Corixa Melacine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm anticipates filing a BLA for its melanoma vaccine in the second quarter of 2001. The application will be based on data from a Phase III study in post-surgical Stage II melanoma patients, which produced a "statistically significant improvement in disease-free survival" in vaccine-treated patient